John Delucca Net Worth

The estimated Net Worth of John Delucca is at least $38.7 Mille dollars as of 9 June 2014. John Delucca owns over 6,764 units of Enzo Biochem stock worth over $38,711 and over the last 21 years John sold ENZ stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Delucca ENZ stock SEC Form 4 insiders trading

John has made over 3 trades of the Enzo Biochem stock since 2014, according to the Form 4 filled with the SEC. Most recently John exercised 6,764 units of ENZ stock worth $166,597 on 9 June 2014.

The largest trade John's ever made was exercising 10,384 units of Enzo Biochem stock on 1 April 2014 worth over $174,451. On average, John trades about 2,104 units every 6 days since 2004. As of 9 June 2014 John still owns at least 34,875 units of Enzo Biochem stock.

You can see the complete history of John Delucca stock trades at the bottom of the page.

What's John Delucca's mailing address?

John's mailing address filed with the SEC is C/O ENZO BIOCHEM INC, 527 MADISON AVENUE, NEW YORK, NY, 10022.

Insiders trading at Enzo Biochem

Over the last 22 years, insiders at Enzo Biochem have traded over $2,615,763 worth of Enzo Biochem stock and bought 1,070,494 units worth $3,103,461 . The most active insiders traders include Bradley Louis Radoff, Management Corp Harbert Dis... e Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of $59,099. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth $11,810.

What does Enzo Biochem do?

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Complete history of John Delucca stock trades at Endo International plc e Enzo Biochem

Enzo Biochem executives and stock owners

Enzo Biochem executives and other stock owners filed with the SEC include:

• Elazar Rabbani,
  Chairman of the Board, Chief Executive Officer, Secretary
• Barry Weiner,
  President, Treasurer
• Dr. Elazar Rabbani Ph.D.,
  Co-Founder, Chairman, Chief Scientific Officer & Sec.
• Barry W. Weiner,
  Founder, Treasurer & Pres
• Dieter Schapfel,
  Chief Medical Director - Enzo Clinical Labs
• Kara Cannon,
  Chief Commercial Officer
• Dr. Dieter Schapfel M.D.,
  Chief Medical Director of Enzo Clinical Labs
• David Bench,
  Chief Financial Officer, Principal Accounting Officer
• David A. Bench,
  CFO & Principal Accounting Officer
• Dov Perlysky,
  Lead Independent Director
• Rebecca Fischer,
  Independent Director
• Ian Walters,
  Independent Director
• Mary Tagliaferri,
  Independent Director
• Kara Cannon,
  Chief Commercial Officer
• Hamid Erfanian,
  CEO & Director
• Bruce A. Dey,
  VP of Sales & Marketing - Enzo Clinical Labs
• Gregory M. Bortz,
  Director
• Bernard L Kasten,
  Director
• David C Goldberg,
  VP CorpDev Pres Enz Clin Labs
• Steven J Pully,
  Director
• Bruce A. Hanna,
  Director
• James Michael O'brien,
  EVP of Finance
• Peter J Iv Clemens,
  10% owner
• Management Corp Harbert Dis...,
  
• Stanford S Warshawsky,
  Director
• Fabian Blank,
  Director
• Christine Fischette,
  Pres., Enzo Therapeutics, Inc.
• Irwin Gerson,
  Director
• John Delucca,
  Director
• Stephen B H Kent,
  Director
• Dean Engelhardt,
  Executive Vice President
• Melvin F Lazar,
  Director
• Barbara E Thalenfeld,
  VP Corporate Development
• John B Sias,
  Director
• Carl W Balezentis,
  Pres., Enzo Life Sciences
• Kevin Krenitsky,
  President, Enzo Clinical Labs
• Shahram K Rabbani,
  COO, Treasurer & Secretary
• Norman E Kelker,
  Senior Vice President
• Herbert B Bass,
  VP of Finance
• Andrew P Whiteley,
  VP BusDev-COO Enzo Lif Sci Inc
• Bradley Louis Radoff,
  Director
• James G. Wolf,
  
• Hamid Erfanian,
  Chief Executive Officer
• Patricia Eckert,
  Chief Financial Officer